-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharming publishes investor presentation on rare-disease portfolio, Joenja and RUCONEST growth strategy

PUBT·04/13/2026 09:38:36
Listen to the news
Pharming publishes investor presentation on rare-disease portfolio, Joenja and RUCONEST growth strategy
  • Pharming outlined 2026 revenue guidance of US$405 million to US$425 million, implying 8% to 13% growth.
  • Operating expense guidance set at US$330 million to US$335 million, implying 6% to 8% growth.
  • Joenja European expansion for patients aged 12+ moved forward with a CHMP positive opinion in March 2026, with potential European Commission clearance in Q2 2026.
  • Japan authorization for Joenja in patients aged 4+ secured in March 2026, supporting pediatric growth plans.
  • Pipeline milestones highlighted leniolisib Phase II topline data targeted in H2 2026, with napazimone (KL1333) FALCON study enrollment completion targeted in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.